Pharmaceutical Executive December 31, 2025
Key Takeaways
- Johnson & Johnson will hold a fireside chat at the JP Morgan Healthcare Conference, potentially announcing significant developments.
- The 2025 acquisition of Intra-Cellular Therapies for $14.6 billion bolstered J&J’s neuroscience portfolio, enhancing care for neuropsychiatric and neurodegenerative disorders.
- In 2024, J&J acquired Ambrx for nearly $2 billion, integrating its ADC technology to advance cancer treatment, particularly in metastatic castration-resistant prostate cancer.
- These acquisitions highlight J&J’s strategic focus on expanding its innovative medicine business and addressing unmet medical needs in neuroscience and oncology.
The pharma giant will likely announce its acquisition plans for the coming year at the healthcare conference.
With the 44th Annual JP Morgan Healthcare Conference less than a month away, the industry is preparing...
Today's Sponsors
Today's Sponsor